Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-43395 in Advanced Solid Tumors and Breast Cancer
NCT06120283Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2023
- Primary completion
- Dec 2029
- Countries
- 11
01
Overview
Phase 1, open-label trial of bgb-43395 in breast cancer and solid tumor (5 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 60 months, Maximum Tolerated Dose at 60 months and 3 more. Started Dec 2023; status: recruiting.
02
Drugs
bgb-43395
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06120283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120283.